Melissa P Wasserstein1, Simon A Jones2, Handrean Soran3, George A Diaz1, Natalie Lippa1, Beth L Thurberg4, Kerry Culm-Merdek5, Elias Shamiyeh5, Haig Inguilizian6, Gerald F Cox7, Ana Cristina Puga8. 1. Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Manchester Centre for Genomic Medicine, St. Mary's Hospital, CMFT, University of Manchester, Manchester, UK. 3. Cardiovascular Trials Unit, Central Manchester University Hospital, Manchester, UK. 4. Pathology, Genzyme, a Sanofi company, Cambridge, MA, USA. 5. Clinical and Experimental Pharmacology, Sanofi, Bridgewater, NJ, USA. 6. Global Safety, Genzyme, a Sanofi company, Cambridge, MA, USA. 7. Clinical Development, Genzyme, a Sanofi company, Cambridge, MA, USA. 8. Clinical Development, Genzyme, a Sanofi company, Cambridge, MA, USA. Electronic address: ana-cristina.puga@genzyme.com.
Abstract
BACKGROUND: Olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is an investigational enzyme replacement therapy (ERT) for patients with ASM deficiency [ASMD; Niemann-Pick Disease (NPD) A and B]. This open-label phase 1b study assessed the safety and tolerability of olipudase alfa using within-patient dose escalation to gradually debulk accumulated sphingomyelin and mitigate the rapid production of metabolites, which can be toxic. Secondary objectives were pharmacokinetics, pharmacodynamics, and exploratory efficacy. METHODS: Five adults with nonneuronopathic ASMD (NPD B) received escalating doses (0.1 to 3.0 mg/kg) of olipudase alfa intravenously every 2 weeks for 26 weeks. RESULTS: All patients successfully reached 3.0mg/kg without serious or severe adverse events. One patient repeated a dose (2.0 mg/kg) and another had a temporary dose reduction (1.0 to 0.6 mg/kg). Most adverse events (97%) were mild and all resolved without sequelae. The most common adverse events were headache, arthralgia, nausea and abdominal pain. Two patients experienced single acute phase reactions. No patient developed hypersensitivity or anti-olipudase alfa antibodies. The mean circulating half-life of olipudase alfa ranged from 20.9 to 23.4h across doses without accumulation. Ceramide, a sphingomyelin catabolite, rose transiently in plasma after each dose, but decreased over time. Reductions in sphingomyelin storage, spleen and liver volumes, and serum chitotriosidase activity, as well as improvements in infiltrative lung disease, lipid profiles, platelet counts, and quality of life assessments, were observed. CONCLUSIONS: This study provides proof-of-concept for the safety and efficacy of within-patient dose escalation of olipudase alfa in patients with nonneuronopathic ASMD.
BACKGROUND: Olipudase alfa, a recombinant humanacid sphingomyelinase (rhASM), is an investigational enzyme replacement therapy (ERT) for patients with ASM deficiency [ASMD; Niemann-Pick Disease (NPD) A and B]. This open-label phase 1b study assessed the safety and tolerability of olipudase alfa using within-patient dose escalation to gradually debulk accumulated sphingomyelin and mitigate the rapid production of metabolites, which can be toxic. Secondary objectives were pharmacokinetics, pharmacodynamics, and exploratory efficacy. METHODS: Five adults with nonneuronopathic ASMD (NPD B) received escalating doses (0.1 to 3.0 mg/kg) of olipudase alfa intravenously every 2 weeks for 26 weeks. RESULTS: All patients successfully reached 3.0mg/kg without serious or severe adverse events. One patient repeated a dose (2.0 mg/kg) and another had a temporary dose reduction (1.0 to 0.6 mg/kg). Most adverse events (97%) were mild and all resolved without sequelae. The most common adverse events were headache, arthralgia, nausea and abdominal pain. Two patients experienced single acute phase reactions. No patient developed hypersensitivity or anti-olipudase alfa antibodies. The mean circulating half-life of olipudase alfa ranged from 20.9 to 23.4h across doses without accumulation. Ceramide, a sphingomyelin catabolite, rose transiently in plasma after each dose, but decreased over time. Reductions in sphingomyelin storage, spleen and liver volumes, and serum chitotriosidase activity, as well as improvements in infiltrative lung disease, lipid profiles, platelet counts, and quality of life assessments, were observed. CONCLUSIONS: This study provides proof-of-concept for the safety and efficacy of within-patient dose escalation of olipudase alfa in patients with nonneuronopathic ASMD.
Authors: Rolf G Boot; Marri Verhoek; Mirjam Langeveld; G Herma Renkema; Carla E M Hollak; Jan J Weening; Wilma E Donker-Koopman; Johanna E Groener; Johannes M F G Aerts Journal: J Inherit Metab Dis Date: 2006-05-30 Impact factor: 4.982
Authors: S L Schissel; X Jiang; J Tweedie-Hardman; T Jeong; E H Camejo; J Najib; J H Rapp; K J Williams; I Tabas Journal: J Biol Chem Date: 1998-01-30 Impact factor: 5.157
Authors: Margaret M McGovern; Tilla Pohl-Worgall; Richard J Deckelbaum; William Simpson; David Mendelson; Robert J Desnick; Edward H Schuchman; Melissa P Wasserstein Journal: J Pediatr Date: 2004-07 Impact factor: 4.406
Authors: Melissa P Wasserstein; Robert J Desnick; Edward H Schuchman; Sabera Hossain; Sylvan Wallenstein; Carin Lamm; Margaret M McGovern Journal: Pediatrics Date: 2004-11-15 Impact factor: 7.124
Authors: Lluis Samaranch; Azucena Pérez-Cañamás; Beatriz Soto-Huelin; Vivek Sudhakar; Jerónimo Jurado-Arjona; Piotr Hadaczek; Jesús Ávila; John R Bringas; Josefina Casas; Haifeng Chen; Xingxuan He; Edward H Schuchman; Seng H Cheng; John Forsayeth; Krystof S Bankiewicz; María Dolores Ledesma Journal: Sci Transl Med Date: 2019-08-21 Impact factor: 17.956
Authors: Margaret M McGovern; Melissa P Wasserstein; Bruno Bembi; Roberto Giugliani; K Eugen Mengel; Marie T Vanier; Qi Zhang; M Judith Peterschmitt Journal: Orphanet J Rare Dis Date: 2021-05-10 Impact factor: 4.123